BioXcel’s Serenity Trial: At-Home Agitation Treatment
BioXcel Therapeutics has reached 33% enrollment (67 patients) in its 200-patient Phase 3 SERENITY At-Home trial for BXCL501 (dexmedetomidine...
Jon Napitupulu
Regeneron and Sanofi: Dupixent® Bullous Pemphigoid Data at AAD
Regeneron and Sanofi announced positive Phase 2/3 trial results for Dupixent (dupilumab) in treating moderate-to-severe bullous pemphigoid (BP), a...
Late-Breaking ESK-001 Phase 2 Data Presented at AAD Meeting
Alumis announced positive 52-week data from the open-label extension of its Phase 2 STRIDE trial for ESK-001, an oral...
Study Shows Increased Cardiometabolic Risk After Switching to Integrase Inhibitors
The AIDS Clinical Trials Group (ACTG) presented data from the REPRIEVE study at the 2025 Conference on Retroviruses and...
aTyr Pharma’s EFZOFITIMOD Shows Promise in Sarcoidosis Treatment
aTyr Pharma’s Phase 3 EFZO-FIT™ study of efzofitimod for pulmonary sarcoidosis received a positive safety review from an independent...
scPharmaceuticals: FDA Approves Expanded Use of FUROSIX for Edema in CKD Patients
The FDA approved scPharmaceuticals’ supplemental New Drug Application for FUROSCIX, expanding its use to treat edema in adults with...
Chemomab’s Nebakitug Shows Promise in Systemic Sclerosis Treatment
Chemomab Therapeutics announced new scientific data supporting the potential of nebokitug (CM-101) as a novel treatment for systemic sclerosis...
Medicus Pharma: Positive Interim Analysis of SKNJC-003 in BCC Treatment
Medicus Pharma (NASDAQ: MDCX) announced positive interim results from its Phase 2 clinical study of SKNJCT-003, a non-invasive treatment...
Clearside Biomedical CLS-AX Phase 3 Wet AMD Trial Announced
Clearside Biomedical announced positive results from a meeting with the FDA regarding its Phase 3 clinical trial plans for...
Rhenium Obisbemeda Gets FDA Orphan Drug Designation
Plus Therapeutics received Orphan Drug Designation from the FDA for its Rhenium (¹⁸⁶Re) Obisbemeda, a treatment for leptomeningeal metastases...